Can You Have Dental Implants with Osteoporosis, Bisphosphonates or Denosumab?

Many people with osteoporosis wonder whether they can replace missing teeth with dental implants, particularly if they take bisphosphonates or denosumab to reduce fracture risk. Osteoporosis and these medicines require careful planning, but they do not automatically rule out implant treatment.

In Short

• Dental implants may be considered for many people with osteoporosis, including some using osteoporosis-dose bisphosphonates or denosumab.
• Antiresorptive treatment does not usually need to be stopped solely for implant placement, but this recommendation is based on low-certainty evidence and decisions should be individualised.
• MRONJ is uncommon at osteoporosis doses but remains an important risk to assess, especially where there is infection, gum disease, smoking, diabetes, corticosteroid use, or previous MRONJ.
• Do not delay or stop denosumab without coordination with the clinician who prescribes it because interruption may increase vertebral-fracture risk.

What are osteoporosis, bisphosphonates and denosumab?

Osteoporosis is a condition in which bones become weaker and more vulnerable to fractures. It affects the skeleton, although the jaw has different healing and loading characteristics from many other bones.

Bisphosphonates and denosumab are antiresorptive medicines. They reduce bone breakdown and are commonly prescribed to lower the risk of osteoporotic fractures. Bisphosphonates may be taken orally or given intravenously, while denosumab is administered by injection at medically scheduled intervals.

These medicines are important for fracture prevention. Because they affect bone turnover, dental surgery may require additional planning in some patients. The key question is not simply whether an implant can be placed, but whether the jaw is likely to heal appropriately and remain healthy around the implant.

Can you have dental implants with osteoporosis?

For many patients treated for osteoporosis, dental implants remain a possible option. The 2025 International ONJ Taskforce concluded that implants may be placed in patients with osteoporosis who are receiving bisphosphonates or denosumab. It also suggested that antiresorptive treatment generally does not need to be stopped before implant placement.

However, this is a weak recommendation based on very low-quality evidence. Research findings are not fully consistent, and individual factors can substantially change the risk profile. Some recent analyses have reported a possible small association between bisphosphonate use and implant-level failure or MRONJ, while the International ONJ Taskforce found no convincing evidence that osteoporosis-dose antiresorptive therapy increases implant failure or compromise.

Osteoporosis or antiresorptive treatment should therefore not be viewed as an automatic contraindication. It should be an important part of the medical and dental assessment before implant surgery.

What is MRONJ and why does it matter?

Medication-related osteonecrosis of the jaw, or MRONJ, is an uncommon but potentially serious complication affecting the jawbone in a person who has received certain antiresorptive or related medicines. It may involve exposed bone or bone that does not heal normally. It can be associated with dental extraction, implant surgery, infection, or trauma, although it does not occur in every patient undergoing dental treatment.

MRONJ is considered rare at standard osteoporosis-treatment doses, but risk is not identical for everyone. Assessment may take into account:

• The type of antiresorptive medicine and how it is administered
• The length of time the medicine has been used
• Whether treatment is for osteoporosis or cancer
• Active periodontal disease or peri-implantitis
• Smoking and diabetes
• Corticosteroid use or other relevant medical conditions
• Oral hygiene and the presence of dental infection
• A previous history of MRONJ
• The need for invasive dental surgery

The presence of a risk factor does not automatically mean implants are unsuitable. It does mean that the potential benefits and risks should be discussed carefully, with preventive dental care and appropriate follow-up.

Are bisphosphonates a contraindication to dental implants?

For patients receiving bisphosphonates at standard doses for osteoporosis, dental implants are not generally considered absolutely contraindicated. The American Dental Association and the American Association of Oral and Maxillofacial Surgeons recognise that elective dentoalveolar surgery is not automatically prohibited in this setting.

Evidence remains limited and somewhat conflicting. A recent meta-analysis reported very-low-certainty evidence of associations between bisphosphonates and implant-level failure or MRONJ. In contrast, the 2025 International ONJ Taskforce found no clear association between osteoporosis antiresorptive therapy and implant failure.

Patients should not be promised a particular outcome, but they should not be denied assessment solely because they take a bisphosphonate. The dental team and prescribing clinician may consider the duration, route, dose, and reason for treatment before making a recommendation.

Can you have implants while taking denosumab?

Some patients taking denosumab for osteoporosis may be considered for dental implants, but denosumab-specific research remains limited. Available studies are few, often small, and heterogeneous, so they do not provide definitive conclusions about MRONJ or implant-complication risk.

Potentially relevant factors include the timing of implant placement, previous bisphosphonate treatment, peri-implantitis, oral infection, and other medical conditions. These factors should be reviewed by the dental team and the clinician managing osteoporosis.

Denosumab should not be independently paused or discontinued for dental surgery. Endocrine Society guidance warns that delaying or stopping denosumab without appropriate follow-on treatment can lead to rebound bone turnover, rapid bone loss, and an increased risk of vertebral fractures.

If a change in medication timing is being considered, it must be coordinated with the prescribing clinician. There is no general recommendation to stop denosumab simply because implant treatment is planned.

When may implant treatment require extra caution?

Implant treatment may require further discussion, delay, or an alternative approach when there is active oral disease or a higher-risk medical situation. Examples include uncontrolled periodontal infection, poor oral hygiene, existing peri-implant disease, previous MRONJ, significant medical comorbidities, or a history of complications after dental surgery.

The risk profile is substantially different for people receiving antiresorptive treatment for cancer. Oncology regimens may involve higher doses or more frequent intravenous or injectable treatment than routine osteoporosis therapy. According to AAOMS guidance, elective dental implants are generally avoided in patients receiving parenteral antiresorptive therapy for cancer. These patients need separate specialist assessment and should not apply osteoporosis-related guidance to their situation without medical advice.

How are patients assessed before dental implants?

A careful consultation is essential. The dental team may review:

• The number and location of missing teeth
• The condition of the gums, remaining teeth, and supporting bone
• Any active infection, periodontal disease, or inflammation
• Your complete medicine list, including dose, route, and duration
• The reason for antiresorptive treatment and whether it is for osteoporosis or cancer
• Smoking, diabetes, steroid use, and other relevant health factors
• Any history of delayed healing, jaw problems, or MRONJ

Dental examination and appropriate imaging help the clinician assess the proposed implant site and identify infection or anatomical concerns. Depending on the case, the dental team may also communicate with the clinician who prescribes osteoporosis treatment.

For international patients travelling to Turkey, it is useful to bring a current medical summary, medication list, recent dental records, imaging, and contact details for the clinician managing osteoporosis. This information helps the clinic make a safer and more realistic treatment plan.

Should bisphosphonates or denosumab be stopped before implants?

Routine discontinuation is not generally recommended solely because a patient is having implant placement. The 2025 International ONJ Taskforce suggested that antiresorptive therapy usually does not need to be stopped before implants, although this recommendation is weak because the available evidence is of very low certainty.

Stopping or changing treatment without medical supervision may create its own risks. This is particularly important with denosumab, where an unplanned interruption can increase bone turnover and fracture risk. A medication break should not be arranged automatically or based only on dental advice.

Any decision about continuing, adjusting, or changing treatment should be made jointly by the relevant qualified clinicians. The dental procedure, fracture risk, reason for medication, and risk of jaw complications all need to be considered together.

What can patients do to prepare?

Preparation focuses on reducing avoidable sources of infection and supporting long-term oral health. Before implant treatment, tell the clinic about gum bleeding, loose teeth, mouth sores, dental pain, or previous healing problems. Existing dental infection or uncontrolled periodontal disease should be assessed before implant placement.

Provide accurate information about every medicine and supplement you take. Do not independently change osteoporosis treatment. Tell the dental and medical teams if you smoke, have diabetes, use corticosteroids, or have another condition that may affect healing.

After treatment, careful oral hygiene and regular professional reviews are important. Inflammation around an implant can develop into peri-implantitis, so bleeding, swelling, discomfort, or looseness should be assessed promptly by a dental professional. Your dentist will provide instructions suited to your procedure and health status.

What are the possible alternatives?

If implants are not suitable or the risks are considered too high, a dentist may discuss other ways to restore function and appearance. The appropriate option depends on the number of missing teeth, the condition of the remaining teeth and gums, personal preferences, and medical history.

Alternatives may include a removable dental prosthesis or another non-implant restoration. These options still require good oral hygiene and professional dental care. A qualified dentist can explain their advantages, limitations, and maintenance requirements.

Frequently asked questions

Does osteoporosis mean I cannot have dental implants?

No. Osteoporosis alone is not generally an absolute contraindication to dental implants. Suitability depends on oral health, medical history, medication regimen, and individual risk assessment.

Are dental implants forbidden with bisphosphonates?

No. Standard osteoporosis-dose bisphosphonate treatment does not automatically rule out implants. Evidence is mixed and uncertain, so the decision should follow assessment by qualified dental and medical professionals.

Can I stop denosumab before implant surgery?

Do not stop or delay denosumab independently. Interruption may cause rebound bone turnover, rapid bone loss, and increased vertebral-fracture risk. Any medication decision must be coordinated with the prescribing clinician.

Is cancer-dose antiresorptive treatment the same as osteoporosis treatment?

No. Oncology regimens can involve higher-dose or more frequent treatment and carry a different MRONJ risk profile. Elective implants are generally avoided in patients receiving parenteral antiresorptive therapy for cancer, according to AAOMS guidance.

Can international patients have an implant assessment in Turkey?

Yes, an assessment can be arranged, but a safe decision requires complete medical and dental information. Bring medication details, relevant reports, imaging, and prescribing-clinician contact information whenever possible.

Conclusion

Many people with osteoporosis can be considered for dental implants, including some patients receiving bisphosphonates or denosumab at osteoporosis doses. Current consensus does not support automatically refusing implants or routinely stopping antiresorptive therapy. Nevertheless, evidence remains limited, MRONJ is an important consideration, and denosumab should not be interrupted without medical coordination.

The safest approach is individualised planning that includes a detailed dental examination, review of medication and medical history, management of oral infection and gum disease, and communication between the dental team and the clinician managing osteoporosis. Estexper Clinic can help international patients understand the assessment process, but final suitability must be determined by qualified physicians and dental professionals after reviewing the complete case.

Medical References

• Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement — International ONJ Taskforce; PubMed.
• Medication-Related Osteonecrosis of the Jaw—2022 Update — American Association of Oral and Maxillofacial Surgeons.
• Osteoporosis Medications and Medication-Related Osteonecrosis of the Jaw — American Dental Association.
• Effects of Bisphosphonates and Denosumab on Dental Implants: A Systematic Review With Meta-Analysis — PubMed; Clinical Oral Implants Research.
• MRONJ Risk Related to Dental Implants in Osteoporosis Treated With Denosumab: A Systematic Review — PubMed; Oral Diseases.
• Pharmacological Management of Osteoporosis in Postmenopausal Women: Guideline Resources — Endocrine Society.